Three-dimensional visualization and evaluation of hilar cholangiocarcinoma resectability and proposal of a new classification.
Biliary surgical procedure
Classification
Hilar cholangiocarcinoma
Three-dimensional image
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
05 Aug 2023
05 Aug 2023
Historique:
received:
09
05
2023
accepted:
29
07
2023
medline:
7
8
2023
pubmed:
5
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
As digital medicine has exerted profound influences upon diagnosis and treatment of hepatobiliary diseases, our study aims to investigate the accuracy of three-dimensional visualization and evaluation (3DVE) system in assessing the resectability of hilar cholangiocarcinoma (hCCA), and explores its potential clinical value. The discovery cohort, containing 111 patients from April 2013 to December 2019, was retrospectively included to determine resectability according to revised criteria for unresectability of hCCA. 3D visualization models were reconstructed to evaluate resectability parameters including biliary infiltration, vascular involvement, hepatic atrophy and metastasis. Evaluation accuracy were compared between contrast-enhanced CT and 3DVE. Logistic analysis was performed to identify independent risk factors of R0 resection. A new comprehensive 3DVE classification of hCCA based on factors influencing resectability was proposed to investigate its role in predicting R0 resection and prognosis. The main outcomes were also analyzed in cohort validation, including 34 patients from January 2020 to August 2022. 3DVE showed an accuracy rate of 91% (95%CI 83.6-95.4%) in preoperatively evaluating hCCA resectability, significantly higher than 81% (95%CI 72.8-87.7%) of that of CT (p = 0.03). By multivariable analysis, hepatic artery involvement in 3DVE was identified an independent risk factor for R1 or R2 resection (OR = 3.5, 95%CI 1.4,8.8, P < 0.01). New 3DVE hCCA classification was valuable in predicting patients' R0 resection rate (p < 0.001) and prognosis (p < 0.0001). The main outcomes were internally validated. 3DVE exhibited a better efficacy in evaluating hCCA resectability, compared with contrast-enhanced CT. Preoperative 3DVE demonstrated hepatic artery involvement was an independent risk factor for the absence of R0 margin. 3DVE classification of hCCA was valuable in clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
As digital medicine has exerted profound influences upon diagnosis and treatment of hepatobiliary diseases, our study aims to investigate the accuracy of three-dimensional visualization and evaluation (3DVE) system in assessing the resectability of hilar cholangiocarcinoma (hCCA), and explores its potential clinical value.
MATERIALS AND METHODS
METHODS
The discovery cohort, containing 111 patients from April 2013 to December 2019, was retrospectively included to determine resectability according to revised criteria for unresectability of hCCA. 3D visualization models were reconstructed to evaluate resectability parameters including biliary infiltration, vascular involvement, hepatic atrophy and metastasis. Evaluation accuracy were compared between contrast-enhanced CT and 3DVE. Logistic analysis was performed to identify independent risk factors of R0 resection. A new comprehensive 3DVE classification of hCCA based on factors influencing resectability was proposed to investigate its role in predicting R0 resection and prognosis. The main outcomes were also analyzed in cohort validation, including 34 patients from January 2020 to August 2022.
RESULTS
RESULTS
3DVE showed an accuracy rate of 91% (95%CI 83.6-95.4%) in preoperatively evaluating hCCA resectability, significantly higher than 81% (95%CI 72.8-87.7%) of that of CT (p = 0.03). By multivariable analysis, hepatic artery involvement in 3DVE was identified an independent risk factor for R1 or R2 resection (OR = 3.5, 95%CI 1.4,8.8, P < 0.01). New 3DVE hCCA classification was valuable in predicting patients' R0 resection rate (p < 0.001) and prognosis (p < 0.0001). The main outcomes were internally validated.
CONCLUSIONS
CONCLUSIONS
3DVE exhibited a better efficacy in evaluating hCCA resectability, compared with contrast-enhanced CT. Preoperative 3DVE demonstrated hepatic artery involvement was an independent risk factor for the absence of R0 margin. 3DVE classification of hCCA was valuable in clinical practice.
Identifiants
pubmed: 37542314
doi: 10.1186/s12957-023-03126-2
pii: 10.1186/s12957-023-03126-2
pmc: PMC10403901
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
239Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Ann Surg. 2009 Aug;250(2):210-8
pubmed: 19638920
Ann Surg Oncol. 2018 Apr;25(4):845-847
pubmed: 28752469
Surg Gynecol Obstet. 1975 Feb;140(2):170-8
pubmed: 1079096
J Hepatobiliary Pancreat Sci. 2014 Aug;21(8):525-32
pubmed: 24616395
Eur Radiol. 2019 Dec;29(12):6458-6468
pubmed: 31254061
Br J Surg. 2020 Nov;107(12):e607
pubmed: 32924154
J Hepatobiliary Pancreat Sci. 2015 Mar;22(3):181-96
pubmed: 25691463
Abdom Radiol (NY). 2017 Mar;42(3):851-860
pubmed: 27770159
Hepatobiliary Pancreat Dis Int. 2015 Dec;14(6):626-32
pubmed: 26663011
J Gastrointest Surg. 1999 Jul-Aug;3(4):369-73
pubmed: 10482688
Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9
pubmed: 11573044
Biomed Res Int. 2015;2015:497942
pubmed: 26448940
World J Surg. 2016 Oct;40(10):2451-9
pubmed: 27206402
HPB (Oxford). 2011 Jul;13(7):483-93
pubmed: 21689232
Eur Radiol. 2006 Oct;16(10):2317-25
pubmed: 16622690
Front Surg. 2021 Aug 19;8:715005
pubmed: 34490337
J Gastroenterol Hepatol. 2010 Feb;25(2):286-92
pubmed: 19780880
AJR Am J Roentgenol. 2008 Feb;190(2):396-405
pubmed: 18212225
Eur Radiol. 2008 Oct;18(10):2213-21
pubmed: 18463877
Insights Imaging. 2011 Oct;2(5):525-531
pubmed: 22347972
Br J Surg. 2020 Jun;107(7):906-916
pubmed: 32057096
Ann Surg. 2018 Jul;268(1):127-133
pubmed: 28288065
Ann Oncol. 2015 Sep;26(9):1930-1935
pubmed: 26133967
J Am Coll Surg. 2015 Jan;220(1):28-37
pubmed: 25456781
Ann Surg Oncol. 2016 Aug;23(Suppl 4):475-484
pubmed: 27387681
Radiology. 2006 Apr;239(1):113-21
pubmed: 16467211
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):490-6
pubmed: 19806295
J Gastroenterol. 2012 Nov;47(11):1165-76
pubmed: 22847554
Radiographics. 2002 Jan-Feb;22(1):173-87
pubmed: 11796906
Hepatol Int. 2020 Jul;14(4):437-453
pubmed: 32638296
EBioMedicine. 2019 Mar;41:693-701
pubmed: 30773479
World J Gastroenterol. 2016 Feb 28;22(8):2601-10
pubmed: 26937148
Hepatology. 2021 Jan;73 Suppl 1:128-136
pubmed: 32438491
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):476-89
pubmed: 19851704
Nat Rev Dis Primers. 2021 Sep 9;7(1):65
pubmed: 34504109
Int J Hyperthermia. 2019 Jan 1;35(1):122-132
pubmed: 30300036
Ann Surg. 2013 Jul;258(1):129-40
pubmed: 23059502
Ann Surg Oncol. 2008 Jul;15(7):1871-9
pubmed: 18454297